Pharmacovigilance and side effects
Globe
medac group
|
All Countries

Oncology

Temomedac

Product Description

Temomedac is a cancer medicine that contains the active substance temozolomide that is used in the tratment of malignant glioma (brain tumours). Temozolomide belongs to a group of cancer medicines called alkylating agents. In the body, temozolomide is converted to another compound called MTIC. MTIC binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide, slowing down the growth of tumours.

Active Ingredient

Temozolomide

Mode of Action

Temozolomide is a triazene that is rapidly chemically hydrolysed at physiological pH to the active metabolite 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC).

MTIC hydrolyses spontaneously to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is thought to be an active alkylating substance.

The cytotoxicity of MTIC is mainly attributed to alkylation at the O-6 position of guanine with additional alkylation at the N-7 position. Aberrant repair of the methyl adduct is thought to play a role in later cytotoxic lesions.

Indication

  • Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment
  • Children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy

Dosage

Hard Capsules:

  • 5 mg
  • 20 mg
  • 100 mg
  • 140 mg
  • 180 mg
  • 250 mg

Not all pack sizes may be marketed.

Materials

Abbreviated product information

Open link External Link

Discover more

Rheumatology

Key rheumatological treatment improved

Rheumatic diseases imply a range of chronic treatment needs across a broad spectrum of patients. With the optimisation of a key treatment in this area, medac has succeeded in bringing a significant improvement to patients' quality of life.
Find out more External

Urology

Addressing unmet needs with urological therapies

Urology is a focus area of highest importance for medac. We have been active in this field from almost the very beginning of our company and are focused on supplying a range of proprietary products that address a variety of unmet therapeutic needs.
Find out more External

Hematology

Innovative and life-saving treatment options

Hematology is a focus area of high importance for medac. To find new treatment approaches for rare diseases, medac addresses critical needs in hematology and has developed innovative products for therapies before and after stem cell transplantation.
Find out more External